NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP) Reports Increase In Q2 Revenue Despite Wider Net Losses
CRISPR Therapeutics (CRSP) recently reported second-quarter results with a significant year-over-year increase in revenue, although net losses also widened. The company's addition to multiple Russell Indices on June 30, 2025, likely buoyed investor sentiment, alongside advancements in its in vivo cardiovascular disease programs. Despite ongoing financial challenges, these positive developments might have bolstered the company's stock, which experienced a 43% price increase over the last...